Patent · US Expired

Modulation of biological signal transduction by RNA interference

US7399586B2 · kind B2 · utility

17Cited by
8References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 23, 2003
Grant dateJul 15, 2008
Priority date
Expiry dateNov 30, 2024

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/53
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods relating to small interfering RNA (siRNA) polynucleotides are provided as pertains to modulation of biological signal transduction. Shown are siRNA polynucleotides that interfere with expression of members of the protein tyrosine phosphatase (PTP) class of enzymes that mediate signal transduction, and with certain MAP kinase kinases (MKK). In certain preferred embodiments siRNA modulate signal transduction pathways comprising SHP2, cdc14a/b, cdc25A/B/C, KAP, PTP-ε, PRL-3, CD45, dual specificity phosphatase-3 (DSP-3), MKK-4, and/or MKK-7. Modulation of PTP-mediated biological signal transduction has uses in diseases associated with defects in cell proliferation, cell differentiation and/or cell survival, such as metabolic disorders (including diabetes and obesity), cancer, autoimmune disease, infectious and inflammatory disorders and other conditions. The invention also provides siRNA polynucleotides that interfere with expression of chemotherapeutic target polypeptides, such as DHFR, thymidylate synthetase, and topoisomerase I.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.